Literature DB >> 20849855

Pathogenesis of cholestatic liver disease and therapeutic approaches.

Gideon M Hirschfield1, E Jenny Heathcote, M Eric Gershwin.   

Abstract

Cholestatic liver disorders are caused by genetic defects, mechanical aberrations, toxins, or dysregulations in the immune system that damage the bile ducts and cause accumulation of bile and liver tissue damage. They have common clinical manifestations and pathogenic features that include the responses of cholangiocytes and hepatocytes to injury. We review the features of bile acid transport, tissue repair and regulation, apoptosis, vascular supply, immune regulation, and cholangiocytes that are associated with cholestatic liver disorders. We now have a greater understanding of the physiology of cholangiocytes at the cellular and molecular levels, as well as genetic factors, repair pathways, and autoimmunity mechanisms involved in the pathogenesis of disease. These discoveries will hopefully lead to new therapeutic approaches for patients with cholestatic liver disease.
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20849855     DOI: 10.1053/j.gastro.2010.09.004

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  86 in total

1.  The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway.

Authors:  Dong-ke Yu; Cai-xia Zhang; Shuang-shuang Zhao; Sheng-hua Zhang; Hao Zhang; Shi-ying Cai; Rong-guang Shao; Hong-wei He
Journal:  Acta Pharmacol Sin       Date:  2015-03-16       Impact factor: 6.150

Review 2.  Management of primary sclerosing cholangitis: conventions and controversies.

Authors:  Natasha Chandok; Gideon M Hirschfield
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

Review 3.  NKT cells in liver diseases.

Authors:  Shasha Zhu; Huimin Zhang; Li Bai
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

4.  Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.

Authors:  Alexander G Miethke; Wujuan Zhang; Julia Simmons; Amy E Taylor; Tiffany Shi; Shiva Kumar Shanmukhappa; Rebekah Karns; Shana White; Anil G Jegga; Celine S Lages; Stephenson Nkinin; Bradley T Keller; Kenneth D R Setchell
Journal:  Hepatology       Date:  2015-08-21       Impact factor: 17.425

5.  [Autoimmune liver diseases].

Authors:  N Pannicke; C Schramm; A W Lohse
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

6.  Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses.

Authors:  Qiao-Ling Yang; Fan Yang; Jun-Ting Gong; Xiao-Wen Tang; Guang-Yun Wang; Zheng-Tao Wang; Li Yang
Journal:  Acta Pharmacol Sin       Date:  2016-08-08       Impact factor: 6.150

Review 7.  Genetics in PBC: what do the "risk genes" teach us?

Authors:  Gideon M Hirschfield; Katherine A Siminovitch
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

8.  The biliary epithelium presents antigens to and activates natural killer T cells.

Authors:  Elisabeth Schrumpf; Corey Tan; Tom H Karlsen; Jon Sponheim; Niklas K Björkström; Olav Sundnes; Kristian Alfsnes; Arthur Kaser; Douglas M Jefferson; Yoshiyuki Ueno; Tor J Eide; Guttorm Haraldsen; Sebastian Zeissig; Mark A Exley; Richard S Blumberg; Espen Melum
Journal:  Hepatology       Date:  2015-05-20       Impact factor: 17.425

9.  Identification of a candidate stem cell in human gallbladder.

Authors:  Rohan Manohar; Yaming Li; Helene Fohrer; Lynda Guzik; Donna Beer Stolz; Uma R Chandran; William A LaFramboise; Eric Lagasse
Journal:  Stem Cell Res       Date:  2015-02-07       Impact factor: 2.020

Review 10.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.